Paliperidone (Invega): risperidone's active metabolite, on its own

Paliperidone, sold as Invega, is what risperidone becomes after the liver finishes processing it. Chemically known as 9-hydroxyrisperidone, paliperidone has been used clinically as its own medication since FDA approval in 2006. It is best known today not for its oral form but for its long-acting injectable family — Invega Sustenna (monthly), Invega Trinza (every three months), and Invega Hafyera (every six months) — among the most widely used long-acting antipsychotics in the world.

What paliperidone is

Paliperidone is the major active metabolite of risperidone. Where risperidone needs the liver enzyme CYP2D6 to be converted into the active form, paliperidone is already active. This means paliperidone has fewer drug-drug interactions through that pathway and is excreted primarily by the kidneys rather than processed extensively by the liver. The full FDA label is available through Drugs@FDA.

How it works

Paliperidone blocks dopamine D2 and serotonin 5-HT2A receptors — the same primary mechanism as risperidone. It also has effects at adrenergic and histaminergic receptors. Its receptor profile and clinical effects largely mirror risperidone's, with one practical difference: the slow-release oral form (OROS technology) gives a smoother blood concentration curve, which may translate to fewer side-effect peaks.

What it treats

• Schizophrenia in adults and adolescents
• Schizoaffective disorder — both monotherapy and adjunct to mood stabilisers/antidepressants

Forms and dosing range

Paliperidone is available as:

• Invega (oral) — extended-release once daily, FDA-labelled adult range typically 3 to 12 mg
• Invega Sustenna — monthly intramuscular injection
• Invega Trinza — every-three-month injection (only after stabilisation on monthly Sustenna for at least four months)
• Invega Hafyera — every-six-month injection (only after stabilisation on Trinza or Sustenna)

Specific dosing should always come from your prescriber. The progression from monthly to three-month to six-month dosing is sequential — you cannot start with the longer intervals.

Why long-acting injectables matter

One of the central challenges in schizophrenia treatment is medication adherence. Missed doses are the leading driver of relapse. Long-acting injectables (LAIs) eliminate the daily decision and the daily reminder — the medication is in the body whether the patient wakes up motivated or not. Multiple meta-analyses summarised by NIMH and the NICE schizophrenia guidelines show LAIs reduce hospitalisation rates compared with oral equivalents, particularly in patients with prior adherence issues or recent first episodes.

Common side effects

• Akathisia — common
• Extrapyramidal symptoms (tremor, stiffness) — see EPS guide
• Sedation
• Weight gain — moderate
• Increased prolactin — often more than other atypicals; can cause menstrual changes, breast tenderness, sexual dysfunction, and in long-term use, bone density concerns
• Headache, dizziness
• Injection-site reactions with the LAIs

Serious side effects

• QT prolongation (less than ziprasidone but still possible)
• Tardive dyskinesia with long-term use
• Neuroleptic malignant syndrome (rare)
• Boxed warning for increased mortality in elderly patients with dementia-related psychosis

Prolactin elevation

Paliperidone, like risperidone, raises serum prolactin more than most other atypicals. In the short term this can cause breast tenderness, milk production unrelated to pregnancy (galactorrhoea), and menstrual irregularities. In the long term, sustained high prolactin can affect bone density and sexual function. This is worth discussing with your prescriber, particularly for younger patients on long-term treatment.

What patients commonly say

• "The injection means I don't have to think about it every day. That alone changed my life."
• "I had stiffness for the first month, but it eased."
• "My periods stopped, which scared me until my doctor explained the prolactin issue."
• "It works the same as risperidone did but is smoother somehow."

Questions for your prescriber

• Would the LAI form be a good fit for me?
• If I start with the oral, when might we consider the injectable?
• How often will my prolactin be checked?
• What should I watch for in terms of movement effects?
• What happens if I miss a scheduled injection?

Putting it together

Paliperidone is a workhorse of modern schizophrenia care — particularly in its long-acting forms. The receptor profile is essentially risperidone's, so the side effects are largely familiar to anyone who has tried that drug. The advantage is the dosing flexibility: from a daily pill to a twice-yearly injection, paliperidone can match a wide range of patient circumstances.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.